These beneficial outcomes are attributed to oxaliplatin-induced secretion of chemokines by tumor-associated macrophages, attracting T cells, and enhancing CAR-T cell infiltration, thereby remodeling the TME to make tumors more sensitive to anti-PD-L1 treatment [89]. The gene discussed is CD274; the disease is neoplasm.